President Trump Signs Legislation Prohibiting Pharmacy Gag Clauses

Insurers and pharmacy benefit managers (PBMs) can no longer restrict pharmacies from providing drug price information to customers. On Wednesday, during a live webcast from the White House, President Trump signed into law a pair of bipartisan bills that has made 'gag clauses' in contracts an illegal practice.

"These clauses prevent pharmacists from telling patients about more affordable options for prescription drugs," said Trump, who called the gag clauses "unjust." "Our citizens deserve to know the lowest price."

The Patient Right to Know Drug Prices Act prohibits insurers and PBMs from restricting a pharmacy’s ability to provide drug price information to a plan enrollee when there is a difference between the cost of the drug under the plan and the cost of the drug when purchased without insurance. Under current contracts with ‘gag clauses,’ pharmacists are prohibited from proactively sharing with customers if their prescription would cost less if they paid out-of-pocket, rather than utilizing an insurance plan. Pharmacists face significant penalties for disobeying these clauses.1-2

The Know the Lowest Price Act provides the same protection for individuals who are covered by Medicare Advantage and Medicare Part D plans.1

House Lawmakers Pass Bills to Prohibit Pharmacy Gag Clauses

ASHP CEO Paul W. Abramowitz, PharmD, ScD (Hon.), FASHP, who attended the bill signings at the White House, expressed his and the organization's support for the laws.3 

"ASHP, independently and as a lead member for of the Steering Committee for the Campaign for Sustainable RxPricing, has long advocated for measures that would improve transparency in drug pricing," said Abramowitz, in a prepared statement.3 "We applaud Congress an the President for enacting legislation that will help pharmacists identify less expensive alternatives for their patients." 

The 2 new laws had received bipartisan support in the House and Senate. "If there’s anything that’s bipartisan, it’s lowering drug prices," said Trump.

Legislation targeting 'gag clauses', as well as overpayments, for lowering patient expenses had been recommended by researchers with a study published in JAMA.3  

Overpayments at point-of-sale were common with 23% of all prescriptions and 28% of generic prescriptions affected, according to the study's data. Study authors wrote that the insurer or PBM retains the difference when patients are overcharged.1,4 The researchers also noted that increased cost may exacerbate a patient’s inability to adhere to a prescription and elevate the risk of negative outcomes.4

According to an earlier statement from the office of Sen. Susan Collins (R-ME), an author on both bills along with Sen. Claire McCaskill (D-MO), several health care organizations supported the legislation including the National Community Pharmacists Association (NCPA), the American Medical Association, the Alliance for Transparent and Affordable Prescriptions, the ERISA Industry Committee, the Pharmaceutical Care Management Association, and America’s Health Insurance Plans. 

In addition to addressing gag clauses, Trump said the pair of bills signed into law will lower drug prices. Supply and demand, which he said was not in place prior to the new laws, will now have an effect on the cost of prescription medications to consumers. 

"Our citizens deserve to know the lowest price. They’ll be able to see prices and see where to go. As they leave pharmacies, those pharmacies will be dropping their prices," said Trump.

This article originally appeared on Pharmacy Times.


  1. Bipartisan Bills to Prohibit “Gag Clauses” That Cause Consumers to Overpay for Prescription Drugs Head to President’s Desk [news release]. Washington, DC; September 25, 2018; Senator Susan Collins website. Accessed September 26, 2018.
  2. Bipartisan Bill to Prohibit “Gag Clauses” That Can Cause Consumers to Overpay for Prescriptions Passes Senate [news release]. Washington, DC; September 17, 2018; Senator Susan Collins website. Accessed September 26, 2018.
  3. ASHP CEO Attends White House Bill Signing on Pharmacy Gag Clause [news release]. 
  4. Van Nuys K. Joyce G. Ribero R. Goldman D. Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs. JAMA. 2018;319(10):1045-1047. doi:10.1001/jama.2018.0102. Accessed September 26, 2018.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses how to optimize collaboration among the health care team to prepare for changes that occur throughout the course of a patient's care.
The convenience of home infusion for these products is very enticing for patients who require them and positioning home infusion pharmacies as partners with prescribers and patients is critical to help support this influx of new therapies.
The oncology pharmaceutical market is rapidly growing and changing.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.